guest ::
| Home > Publications database > Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer. |
| Home > Publications database > Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer. |
| Journal Article | DKFZ-2025-00980 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
BMJ Publishing Group
London
This record in other databases: 
Please use a persistent id in citations: doi:DOI:10.1136/gutjnl-2024-333238 doi:DOI:10.1136/gutjnl-2024-333238
Abstract: RAS mutations are frequently observed in human cholangiocarcinoma (CCA), while they are relatively rare in hepatocellular carcinoma (HCC). The role of RAS-dependent signalling pathways in CCA development is currently not well understood.The objective of this study was to investigate RAS-dependent signalling pathways in CCA and their role in tumour development and differentiation.We used genetically engineered mouse models with liver-specific deletion of tumour suppressors Rb and p53 together with activation of oncogenic Kras to investigate the cell of origin in intrahepatic CCA and to elucidate the role of RAS-dependent signalling pathways in CCA development.In mice, Kras-mutant intrahepatic CCA develops primarily from hepatocytes and shows activation of PI3K/AKT and MEK/ERK signalling downstream of KRAS. Targeted genetic inactivation of each of these pathways leads to delayed tumour growth and profound alterations in tumour differentiation. Specifically, reduced PI3K/AKT signalling promotes more well-differentiated tumours, whereas the inactivation of MEK/ERK signalling induces a differentiation switch towards a more hepatocyte-like phenotype. This switch is accompanied by activation of WNT/β-catenin signalling, a pathway commonly activated in human HCC.These findings provide insights into the role of RAS-dependent pathways in liver cancer differentiation and offer a compelling explanation for the high prevalence of RAS mutations in human CCA compared with HCC.
Keyword(s): CANCER GENETICS ; CHOLANGIOCARCINOMA ; HEPATOBILIARY CANCER
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; National-Konsortium ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
